STAT3 Archives - Kymera Therapeutics

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

6/5/22

STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis

6/1/22

STAT3 Degraders Inhibit Cellular Activation, Cytokine Production, and Th17 Development, Resulting in Profound Inhibition of Autoimmunity in the MOG-EAE Model of CNS Inflammation

5/3/22

The 63rd Annual ASH Meeting and Exposition, December 13, 2021

12/13/21

The 63rd Annual ASH Meeting and Exposition, December 11-14, 2021

12/13/21

SITC 2021, November 10-14, 2021

11/12/21

13th Annual T-Cell Lymphoma Forum, July 8-10, 2021

7/12/21

Ligase Targeting Drug Development Summit, May 25 – 27, 2021

5/26/21

Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC, February 16-17, 2021

2/16/21

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020

12/7/20

×